Literatur zum Artikel Kollewe et al.

• References

• 1 Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN. et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 2007; Aug 8 (Suppl. 04) 195-213.
• 2 Abrahams S, Goldstein LH, Kew JJ, Brooks DJ, Lloyd CM, Frith CD. et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1999; 119 Pt 6 2105-2120.
• 3 Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta neurologica Scandinavica 1983; 68 (Suppl. 01) 20-29.
• 4 Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118 Pt 3 707-719.
• 5 Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D. et al. Amyotrophic lateral sclerosis in an urban setting : A population based study of inner city London. J Neurol 2006; 253 (Suppl. 12) 1642-1643.
• 6 Bobowick AR, Brody JA. Epidemiology of motorneuron diseases. The New England journal of medicine 1973; 288 (Suppl. 20) 1047-1055.
• 7 Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathology and applied neurobiology 1998; 24 (Suppl. 02) 104-117.
• 8 Brugman F, Wokke JH, Vianney de Jong JM, Franssen H, Faber CG, Van den Berg LH. Primary lateral sclerosis as a phenotypic manifestation of familial ALS. Neurology 2005; 64 (Suppl. 10) 1778-1779.
• 9 Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN. et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005; 12 (Suppl. 12) 921-938.
• 10 Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K. et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004. Eur J Neurol 2004; 11 (Suppl. 09) 577-581.
• 11 Li TM, Day SJ, Alberman E, Swash M. Differential diagnosis of motoneurone disease from other neurological conditions. Lancet 1986; 2 8509 731-733.
• 12 Meininger V. Getting the diagnosis right: beyond El Escorial. J Neurol 1999; 246 (Suppl. 03) III10-2.
• 13 Wilbourn AJ. Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria. J Neurol Sci 1998; 160 (Suppl. 01) S25-9.
• 14 Chio A. ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999; 246 (Suppl. 03) III1-5.
• 15 Chio A. Update on ISI survey: Europe, North America and South America. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 (Suppl. 01) S9-11.
• 16 Dengler R, Troger M. Impact of riluzole on the relationship between patient and physician. J Neurol 1997; 244 (Suppl. 02) S30-2.
• 17 Bromberg M. Accelerating the diagnosis of amyotrophic lateral sclerosis. The neurologist 1999; 5: 63-74.
• 18 Aggarwal A, Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002; 73 (Suppl. 02) 199-201.
• 19 Lima AF, Evangelista T, de Carvalho M. Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyography and clinical neurophysiology 2003; 43 (Suppl. 03) 189-192.
• 20 Evangelista T, Carvalho M, Conceicao I, Pinto A, de Lurdes M, Luis ML. Motor neuropathies mimicking amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci 1996; 139 Suppl 95-98.
• 21 Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Archives of neurology 2000; 57 (Suppl. 01) 109-113.
• 22 Belsh JM, Schiffman PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. J Neurol Sci 1996; 139 Suppl 110-116.
• 23 Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996; 60 (Suppl. 02) 147-151.
• 24 Brooks BR. Earlier is better: the benefits of early diagnosis. Neurology 1999; 53 8 Suppl 5 S53-4 discussion S5-7.
• 25 Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 (Suppl. 05) 293-299.
• 26 Ross MA, Miller RG, Berchert L, Parry G, Barohn RJ. Armon et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998; 50 (Suppl. 03) 768-772.
• 27 Leigh PN, Abrahams S, Al-Chalabi A, Ampong MA, Goldstein LH, Johnson J. et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003; 74 (Suppl. 04) iv32-iv47.
• 28 Lind SE, DelVecchio Good MJ, Seidel S, Csordas T, Good BJ. Telling the diagnosis of cancer. J Clin Oncol 1989; 7 (Suppl. 05) 583-589.
• 29 Doyle D, O’Connell S. Breaking bad news: starting palliative care. Journal of the Royal Society of Medicine 1996; 89 (Suppl. 10) 590-591.
• 30 Davies E, Hopkins A. Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working Group, Royal College of Physicians. British journal of neurosurgery 1997; 11 (Suppl. 04) 318-330.
• 31 Damian D, Tattersall MH. Letters to patients: improving communication in cancer care. Lancet. 1991 Oct 12 338 8772 923-5.
• 32 Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R. et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52 (Suppl. 07) 1311-1323.
• 33 Borasio GD, Sloan R, Pongratz DE. Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 (Suppl. 01) S127-33.
• 34 McCluskey L, Casarett D, Siderowf A. Breaking the news: a survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 (Suppl. 03) 131-135.
• 35 Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2 (Suppl. 03) 159-164.
• 36 Ackerman GM, Oliver DJ. Psychosocial support in an outpatient clinic. Palliative medicine 1997; 11 (Suppl. 02) 167-168.
• 37 Chio A, Silani V. Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers. J Neurol Sci 2001; 191 1–2 145-150.
• 38 Howard RS, Orrell RW. Management of motor neurone disease. Postgraduate medical journal 2002; 78 (Suppl. 926) 736-741.
• 39 Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry 2003; 74 (Suppl. 09) 1258-1261.
• 40 Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995; 132 (Suppl. 02) 207-215.
• 41 Chio A, Mora G, Balzarino Mutani R. Interdisciplinary ALS-Centres: Effect of survival and use of health services in a population-based survey. Neurology 2004 62. 05
• 42 Brooks BR, Belden DS, Roelke K. Survival in Non-Riluzole treated ALS patients is identical before and since 1996: a clinic-based epidemiological study. ALS and other motor neuron disorders 2001; 2 (Suppl. 02) 60-61.
• 43 Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3 (Suppl. 01) 15-21.
• 44 Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996–2000. J Neurol 2003; 250 (Suppl. 04) 473-479.
• 45 Andersen PM, Sims KB, Xin WW, Kiely R, O’Neill G, Ravits J. et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4 (Suppl. 02) 62-73.
• 46 Silani V, Cova L, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet 2004; 364 9429 200-202.
• 47 Czaplinski A, Schweikert K, Strobel W, Steck AJ, Weber M. [Symptomatic management in amyotrophic lateral sclerosis (ALS)). Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine. Praxis 2006; 95 (Suppl. 08) 263-268 9-71.
• 48 Forshew DA, Bromberg MB. A survey of clinicians’ practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4 (Suppl. 04) 258-263.
• 49 Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17 (Suppl. 06) 1318-1320.
• 50 Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. Archives of pediatrics & adolescent medicine 2000; 154 (Suppl. 12) 1214-1218.
• 51 Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary flow in amyotrophic lateral sclerosis with Scopoderm TTS. Head & neck 1989; 11 (Suppl. 06) 565.
• 52 Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary flow with transdermal scopolamine: a fouryear experience. Otolaryngol Head Neck Surg 1990; 103 (Suppl. 04) 615-618.
• 53 Camp-Bruno JA, Winsberg BG, Green-Parsons AR, Abrams JP. Efficacy of benztropine therapy for drooling. Developmental medicine and child neurology 1989; 31 (Suppl. 03) 309-319.
• 54 Tan EK. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations. Eur J Neurol 2006; 13 (Suppl. 01) 60-64.
• 55 Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I. et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69 (Suppl. 01) 121-123.
• 56 Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 2001; 190 1–2 95-97.
• 57 Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001; 70 (Suppl. 03) 417-418.
• 58 Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001; 70 (Suppl. 04) 538-540.
• 59 Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clinical neurology and neurosurgery 2004; 106 (Suppl. 02) 93-96.
• 60 Andersen PM, Gronberg H, Franzen L, Funegard U. External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis. J Neurol Sci 2001; 191 1–2 111-114.
• 61 Harriman M, Morrison M, Hay J, Revonta M, Eisen A, Lentle B. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. The Journal of otolaryngology 2001; 30 (Suppl. 04) 242-245.
• 62 Stalpers LJ, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 2002; 58 (Suppl. 08) 1308.
• 63 Burton MJ. The surgical management of drooling. Developmental medicine and child neurology 1999; 33 (Suppl. 12) 1110-1116.
• 64 Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. American family physician 2004; 69 (Suppl. 11) 2628-34.
• 65 Janzen VD, Rae RE, Hudson AJ. Otolaryngologic manifestations of amyotrophic lateral sclerosis. The Journal of otolaryngology 1988; 17 (Suppl. 01) 41-42.
• 66 Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139 Suppl 43-44.
• 67 Hanayama K, Ishikawa Y, Bach JR. Amyotrophic lateral sclerosis. Successful treatment of mucous plugging by mechanical insufflation-exsufflation. American journal of physical medicine & rehabilitation / Association of Academic Physiatrists 1997; 76 (Suppl. 04) 338-339.
• 68 Sancho J, Servera E, Diaz J, Marin J. Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004; 125 (Suppl. 04) 1400-1405.
• 69 Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta neurologica Scandinavica 1989; 80 (Suppl. 02) 114-117.
• 70 Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE. et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004; 63 (Suppl. 08) 1364-1370.
• 71 Jannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clinical neuropharmacology 1996; 19 (Suppl. 06) 532-535.
• 72 Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. The New England journal of medicine 1985; 312 (Suppl. 23) 1480-1482.
• 73 Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993; 342 8875 837-839.
• 74 Poek K. Pathologisches Lachen und Weinen bei bulbärerer Amyotropher Lateralsklerose. Deutsche Med Wochenschr 1996; 94: 310-314.
• 75 Connolly PS, Shirley EA, Wasson JH, Nierenberg DW. Treatment of nocturnal leg cramps. A crossover trial of quinine vs vitamin E. Archives of internal medicine 1992; 152 (Suppl. 09) 1877-1880.
• 76 Diener HC, Dethlefsen U, Dethlefsen-Gruber S, Verbeek P. Effectiveness of quinine in treating muscle cramps: a double-blind, placebo-controlled, parallel-group, multicentre trial. Int J Clin Pract 2002; 56 (Suppl. 04) 243-246.
• 77 Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191 1–2 133-137.
• 78 Kesiktas N, Paker N, Erdogan N, Gulsen G, Bicki D, Yilmaz H. The use of hydrotherapy for the management of spasticity. Neurorehabilitation and neural repair 2004; 18 (Suppl. 04) 268-273.
• 79 dos Santos MT, de Oliveira LM. Use of cryotherapy to enhance mouth opening in patients with cerebral palsy. Spec Care Dentist 2004; 24 (Suppl. 04) 232-234.
• 80 Norris Jr FH, UKS Sachais B, Carey M. Trial of baclofen in amyotrophic lateral sclerosis. Archives of neurology 1979; 36 (Suppl. 11) 715-716.
• 81 Marquardt G, Seifert V. Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 72 (Suppl. 02) 275-276.
• 82 Rocha JA, Reis C, Simoes F, Fonseca J, Mendes Ribeiro J. Diagnostic investigation and multidisciplinary management in motor neuron disease. J Neurol 2005; 252 (Suppl. 12) 1435-1447.
• 83 Winterholler MG, Heckmann JG, Hecht M, Erbguth FJ. Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin. Neurology 2002; 58 (Suppl. 03) 502-503.
• 84 Dengler R. Current treatment pathways in ALS: a European perspective. Neurology 1999; 53 8 Suppl 5 S4-10 discussion S20-1.
• 85 Miller RG. Examining the evidence about treatment in ALS/MND. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2 (Suppl. 01) 3-7.
• 86 Andersen PM, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, Keranen ML. et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119 Pt 4 1153-1172.
• 87 Jones CT, Swingler RJ, Simpson SA, Brock DJ. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. Journal of medical genetics 1995; 32 (Suppl. 04) 290-292.
• 88 Andersen PM, Nilsson P, Keranen ML, Forsgren L, Hagglund J, Karlsborg M. et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997; 120 Pt 10 1723-1737.
• 89 Gasser T, Dichgans M, Finsterer J, Hausmanowa-Petrusewicz I, Jurkat-Rott K, Klopstock T. et al. EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. First of two parts. Eur J Neurol 2001; 8 (Suppl. 04) 299-314.
• 90 Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124 Pt 10 2000-2013.
• 91 Bourke SC, Williams TL, Bullock RE, Gibson GJ, Shaw PJ. Non-invasive ventilation in motor neuron disease: current UK practice. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3 (Suppl. 03) 145-149.
• 92 Bourke SC, McColl E, Shaw PJ, Gibson GJ. Validation of quality of life instruments in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 (Suppl. 01) 55-60.
• 93 Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 (Suppl. 02) 67-71.
• 94 Annane D, Chevrolet JC, Chevret S, Raphael JC. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane database of systematic reviews (Online) 2000; 2: CD001941.
• 95 Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet neurology 2006; 5 (Suppl. 02) 140-147.
• 96 Mustfa N, Walsh E, Bryant V, Lyall RA, Addington-Hall J, Goldstein LH. et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology 2006; 66 (Suppl. 08) 1211-1217.
• 97 Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci 1996; 139 Suppl 123-128.
• 98 Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57 (Suppl. 11) 939-944.
• 99 Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F, Morice RC. et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliative medicine 2003; 17 (Suppl. 08) 659-663.
• 100 Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 (Suppl. 02) 91-96.
• 101 Heffernan C, Jenkinson C, Holmes T, Feder G, Kupfer R, Leigh PN. et al. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 (Suppl. 02) 72-83.
• 102 Mathus-Vliegen LM, Louwerse LS, Merkus MP, Tytgat GN, Vianney de Jong JM. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointestinal endoscopy 1994; 40 (Suppl. 04) 463-469.
• 103 Shaw AS, Ampong MA, Rio A, Al-Chalabi A, Sellars ME, Ellis C. et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler 2006; 7 (Suppl. 01) 16-21.
• 104 Chio A, Galletti R, Finocchiaro C, Righi D, Ruffino MA, Calvo A. et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry 2004; 75 (Suppl. 04) 645-647.
• 105 Shaw AS, Ampong MA, Rio A, McClure J, Leigh PN, Sidhu PS. Entristar skin-level gastrostomy tube: primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. Radiology 2004; 233 (Suppl. 02) 392-399.
• 106 Thornton FJ, Fotheringham T, Alexander M, Hardiman O, McGrath FP, Lee MJ. Amyotrophic lateral sclerosis: enteral nutrition provision--endoscopic or radiologic gastrostomy?. Radiology 2002; 224 (Suppl. 03) 713-717.
• 107 Scott AG, Austin HE. Nasogastric feeding in the management of severe dysphagia in motor neurone disease. Palliative medicine 1994; 8 (Suppl. 01) 45-49.
• 108 Bak TH, Hodges JR. The effects of motor neurone disease on language: further evidence. Brain and language 2004; 89 (Suppl. 02) 354-361.
• 109 Cobble M. Language impairment in motor neurone disease. J Neurol Sci 1998; 160 (Suppl. 01) S47-52.
• 110 Murphy J. Communication strategies of people with ALS and their partners. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 (Suppl. 02) 121-126.
• 111 Borasio GD. Palliative care in ALS: searching for the evidence base. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2 (Suppl. 01) S31-5.
• 112 Oliver D, Borasio GD, Walsh D. Palliative Care in Amyotrophic Lateral Sclerosis. 2 ed. Oxford: Oxford University Press; 2006
• 113 Mitsumoto H, Bromberg M, Johnston W, Tandan R, Byock I, Lyon M. et al. Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6 (Suppl. 03) 145-54.
• 114 Sykes N, Thorns A. The use of opioids and sedatives at the end of life. The lancet oncology 2003; 4 (Suppl. 05) 312-318.
• 115 Haberlandt WF. Genetic aspects of amyotrophic lateral sclerosis and progressive bulbar paralysis. Acta geneticae medicae et gemellologiae 1959; 8: 369-374.
• 116 Murros K, Fogelholm R. Amyotrophic lateral sclerosis in Middle-Finland: an epidemiological study. Acta neurologica Scandinavica 1983; 67 (Suppl. 01) 41-47.
• 117 Thijs V, Peeters E, Theys P, Matthijs G, Robberecht W. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta neurologica Belgica 2000; 100 (Suppl. 02) 84-90.
• 118 Murray TJ, Pride S, Haley G. Motor neuron disease in Nova Scotia. Canadian Medical Association journal 1974; 110 (Suppl. 07) 814-817.
• 119 Gunnarsson LG, Lygner PE, Veiga-Cabo J, de Pedro-Cuesta J. An epidemic-like cluster of motor neuron disease in a Swedish county during the period 1973–1984. Neuroepidemiology 1996; 15 (Suppl. 03) 142-152.
• 120 Li TM, Alberman E, Swash M. Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 1988; 51 (Suppl. 06) 778-784.
• 121 Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Archives of neurology 1978; 35 (Suppl. 10) 638-642.
• 122 Giagheddu M, Puggioni G, Masala C, Biancu F, Pirari G, Piras MR. et al. Epidemiologic study of amyotrophic lateral sclerosis in Sardinia, Italy. Acta neurologica Scandinavica 1983; 68 (Suppl. 06) 394-404.
• 123 Hojer-Pedersen E, Christensen PB, Jensen NB. Incidence and prevalence of motor neuron disease in two Danish counties. Neuroepidemiology 1989; 8 (Suppl. 03) 151-159.
• 124 Fong KY, Yu YL, Chan YW, Kay R, Chan J, Yang Z. et al. Motor neuron disease in Hong Kong Chinese: epidemiology and clinical picture. Neuroepidemiology 1996; 15 (Suppl. 05) 239-245.
• 125 Jokelainen M. Amyotrophic lateral sclerosis in Finland. II: Clinical characteristics. Acta neurologica Scandinavica 1977; 56 (Suppl. 03) 194-204.
• 126 Corrado L, D’Alfonso S, Bergamaschi L, Testa L, Leone M, Nasuelli N. et al. SOD1 gene mutations in Italian patients with Sporadic Amyotrophic Lateral Sclerosis (ALS). Neuromuscul Disord 2006; 16 (Suppl. 11) 800-804.
• 127 Gellera C, Castellotti B, Riggio MC, Silani V, Morandi L, Testa D. et al. Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations. Neuromuscul Disord 2001; 11 (Suppl. 04) 404-410.
• 128 Shaw CE, Enayat ZE, Chioza BA, Al-Chalabi A, Radunovic A, Powell JF. et al. Mutations in all five exons of SOD-1 may cause ALS. Annals of neurology 1998; 43 (Suppl. 03) 390-394.
• 129 Jackson M, Al-Chalabi A, Enayat ZE, Chioza B, Leigh PN, Morrison KE. Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 cases and identification of a novel insertion mutation. Annals of neurology 1997; 42 (Suppl. 05) 803-807.
• 130 Garcia-Redondo A, Bustos F, Juan YSB, Del Hoyo P, Jimenez S, Campos Y. et al. Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis. Muscle Nerve 2002; 26 (Suppl. 02) 274-278.
• 131 Battistini S, Giannini F, Greco G, Bibbo G, Ferrera L, Marini V. et al. SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study. J Neurol 2005; 252 (Suppl. 07) 782-788.
• 132 Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL. et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Annals of neurology 1997; 41 (Suppl. 02) 210-221.
• 133 Boukaftane Y, Khoris J, Moulard B, Salachas F, Meininger V, Malafosse A. et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. The Canadian journal of neurological sciences 1998; 25 (Suppl. 03) 192-196.
• 134 Niemann S, Joos H, Meyer T, Vielhaber S, Reuner U, Gleichmann M. et al. Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect. J Neurol Neurosurg Psychiatry 2004; 75 (Suppl. 08) 1186-1188.